ABVX
Abivax (ABVX)
Healthcare • NASDAQ • $122.74-1.53%
- Symbol
- ABVX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $122.74
- Daily Change
- -1.53%
- Market Cap
- $9.73B
- Trailing P/E
- N/A
- Forward P/E
- -43.07
- 52W High
- $148.83
- 52W Low
- $5.59
- Analyst Target
- $155.20
- Dividend Yield
- N/A
- Beta
- -0.19
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Company websiteResearch ABVX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.